On January 3, 2024, Mikhail V. Blagosklonny M.D., Ph.D. , from Roswell Park Comprehensive Cancer Center published a new brief report in Oncoscience ( Volume 11 ), entitled, “ My battle with cancer. Part 1 .”
“In January 2023, diagnosed with numerous metastases of lung cancer in my brain, I felt that I must accomplish a mission. If everything happens for a reason, my cancer, in particular, I must find out how metastatic cancer can be treated with curative intent. This is my mission now, and the reason I was ever born. In January 2023, I understood the meaning of life, of my life. I was born to write this article. In this article, I argue that monotherapy with targeted drugs, even when used in sequence, cannot cure metastatic cancer. However, preemptive combinations of targeted drugs may, in theory, cure incurable cancer. Also, I share insights on various topics, including rapamycin, an anti-aging drug that can delay but not prevent cancer, through my personal journey.”
Read the full paper: DOI: https://doi.org/10.18632/oncoscience.593
Correspondence to: Mikhail V. Blagosklonny
Emails: Blagosklonny@oncotarget.com , Blagosklonny@rapalogs.com
Keywords: lung cancer, brain metastases, capmatinib, resistance, MET
About Oncoscience :
Oncoscience is a peer-reviewed, open-access, traditional journal covering the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. This journal has a special mission: Freeing oncology from publication cost. It is free for the readers and the authors.
To learn more about Oncoscience , visit Oncoscience.us and connect with us on social media:
For media inquiries, please contact media@impactjournals.com .
Oncoscience Journal Office
6666 East Quaker Str., Suite 1D
Orchard Park, NY 14127
Phone: 1-800-922-0957, option 4
###
Oncoscience
Commentary/editorial
People
My battle with cancer. Part 1
3-Jan-2024